Specifically, our proposed model can non-invasively predict the expression status of PD-1 and PD-L1 in HCC patients, and achieved a performance of 86.56% AUC, 84.38% ACC, 92.86% Sen, 80.88% Spec, 0.688 Mcc for PD-1, and 83.93% AUC, 83.33% ACC, 85.00% Sen, 82.14% Spec, and 0.671 MCC for PD-L1. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.